Peptide Therapy, Safety, and Legal Compliance

Peptide therapy and other advanced biologic treatments are rapidly evolving areas of medicine. Some treatments may eventually play a role in shoulder injury recovery, rotator cuff healing, postoperative recovery, inflammation control, or biologic optimization.

At this time, any use of peptide therapy or advanced biologic treatment must be approached carefully, legally, ethically, and with patient safety as the primary concern.

Our position on peptide therapy

Dr. Streit’s practice may offer some, all, or none of these treatments at a given time depending on the available scientific evidence, legal status, regulatory guidance, medication sourcing, compounding standards, and patient safety considerations.

Peptide therapy will only be considered when it is medically appropriate, legally permissible, properly sourced, and reasonably supported by available safety information.

Patients should understand that many peptide therapies discussed online are not FDA-approved for orthopaedic or shoulder-specific indications. The FDA has identified safety concerns for certain compounded peptide substances, including concerns related to immunogenicity, impurities, limited human safety data, and uncertainty regarding whether some substances may cause harm in humans.

Patient safety comes first

The goal is not to offer the newest therapy simply because it is popular. The goal is to evaluate emerging treatments responsibly and determine whether they may safely support recovery from shoulder injuries or shoulder surgery.

Before any peptide or advanced biologic treatment is considered, the following questions matter:

• Is the treatment legally available for clinical use?
• Is there adequate safety information in humans?
• Is there evidence relevant to the patient’s specific shoulder condition?
• Is the product sourced from an appropriate medical or pharmaceutical supplier?
• Is the route of administration safe and appropriate?
• Could the treatment interfere with surgery, anesthesia, healing, or other medications?
• Are there better-established treatment options available?

Important limitations

Peptides and biologic therapies should not be viewed as substitutes for accurate diagnosis or proven shoulder treatment.

A peptide cannot reliably reattach a torn rotator cuff, reverse advanced shoulder arthritis, stabilize a shoulder that repeatedly dislocates, correct a displaced fracture, or replace appropriate surgery when surgery is clearly indicated.

When used appropriately, advanced therapies may be considered only as potential adjuncts to a broader treatment plan that may include diagnosis, physical therapy, nutrition, metabolic optimization, injections, surgery, and structured rehabilitation.

Ongoing review and compliance

Because the legal and regulatory environment surrounding peptide therapy continues to evolve, Dr. Streit’s practice will continue to review applicable laws, FDA guidance, compounding standards, safety data, and clinical evidence before offering any peptide-based or advanced biologic treatment.

Treatments that are not legally permissible, not appropriately sourced, not medically appropriate, or not supported by adequate safety review will not be offered.

Patients are encouraged to disclose all peptide use, supplement use, hormone therapies, injections, compounded medications, and nontraditional treatments before shoulder surgery or procedural treatment.

What this means for patients

Dr. Streit is interested in cutting-edge therapies that may improve recovery from shoulder injuries and shoulder surgery. However, innovation must be balanced with safety, evidence, transparency, and legal compliance.

The goal is to responsibly evaluate emerging treatments while protecting patients from unsupported claims, unsafe products, and therapies that have not been adequately studied for human use.